SCHEMBL19917153

SCHEMBL19917153

O=c1[nH]cnc2c1c(C(F)(F)F)nn2C1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 2/20 0.37
NR3C1 P04150 2/20 0.36
KDR P35968 8/20 0.34
PIK3CD O00329 7/20 0.34
ABL1 P00519 7/20 0.34
EGFR P00533 7/20 0.34
HCK P08631 7/20 0.34
SRC P12931 7/20 0.34
PIK3CA P42336 7/20 0.34
PIK3CB P42338 7/20 0.34
MTOR P42345 7/20 0.34
PIK3CG P48736 7/20 0.34
EPHB4 P54760 7/20 0.34
PRKDC P78527 7/20 0.34
PDE9A O76083 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RET P07949 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21138767 0.76 KDR (0.53) KDRPIK3CDABL1EGFRHCK
SCHEMBL21057281 0.74 KDR (0.43) NR3C1KDRPIK3CDABL1EGFR
SCHEMBL18642033 0.72 JAK2 (0.42) KDRPIK3CDABL1EGFRHCK
SCHEMBL2077062 0.69 PDE9A (0.54) PDE9AALDH1A1
SCHEMBL29113651 0.68 PDE9A (0.39) NR3C1PDE9ARET
SCHEMBL29113643 0.68 NR3C1 (0.47) NR3C1KDRPIK3CDPIK3CAPIK3CG
SCHEMBL2078528 0.67 ALDH1A1 (0.54) PDE9AALDH1A1
SCHEMBL25065700 0.67 ABL1 (0.39) KDRABL1EGFRSRCALDH1A1
SCHEMBL21159325 0.67 ABL1 (0.41) ADAMTS5NR3C1KDRPIK3CDABL1
SCHEMBL22086527 0.67 ABL1 (0.39) KDRABL1EGFRSRCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
WO-2018038265-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2018-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND PDE7B, PDE3A, PDE7A ADAMTS5 1261/4885NR3C1 1835/4885KDR 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.